Wei Duo Huang

US Patent:

7097970, Aug 29, 2006

Filed:

Jun 4, 2001

Appl. No.:

09/874475

Inventors:

Christos J. Petropoulos - Half Moon Bay CA, US
Neil T. Parkin - Belmont CA, US
Jeanette M. Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US

Assignee:

Monogram Biosciences, Inc. - South San Francisco CA

International Classification:

C12Q 1/70

US Classification:

435 5, 435 6, 435 71, 435 721, 435 691, 4353201, 514 44, 530 2372

Abstract:

The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

US Patent:

7169551, Jan 30, 2007

Filed:

Dec 29, 2005

Appl. No.:

11/323189

Inventors:

Christos J. Petropoulos - Half Moon Bay CA, US
Neil T. Parkin - Belmont CA, US
Jeanette Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US

Assignee:

Monogram Biosciences, Inc. - South San Franisco CA

International Classification:

C12Q 1/70

US Classification:

435 5, 435 6, 435 71, 435 721, 4353201, 536 2372

Abstract:

The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

US Patent:

7235356, Jun 26, 2007

Filed:

Sep 21, 2005

Appl. No.:

11/233461

Inventors:

Christos J. Petropoulos - Half Moon Bay CA, US
Neil T. Parkin - Belmont CA, US
Jeanette Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US

Assignee:

Monogram Biosciences, Inc. - South San Franisco CA

International Classification:

C12Q 1/70

US Classification:

435 5, 435 6, 435 71, 435 721, 4353201, 536 2372

Abstract:

The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

US Patent:

7370132, May 6, 2008

Filed:

Nov 16, 2005

Appl. No.:

11/281718

Inventors:

Wei Je Huang - Fremont CA, US
Luc R. Bisson - San Jose CA, US
Oren Rubinstein - Sunnyvale CA, US
Michael B. Diamond - Los Gatos CA, US
William B. Simms - San Jose CA, US

Assignee:

Nvidia Corporation - Santa Clara CA

International Classification:

G06F 13/40

US Classification:

710307, 710305, 710310

Abstract:

A bus permits the number of active serial data lanes of a data link to be re-negotiated in response to changes in bus bandwidth requirements. In one embodiment, clock buffers not required to drive active data lanes are placed in an inactive state to reduce clock power dissipation.

US Patent:

8114585, Feb 14, 2012

Filed:

Jun 12, 2007

Appl. No.:

12/304418

Inventors:

Wei Huang - Foster City CA, US

Assignee:

Monogram Biosciences, Inc. - South San Francisco CA

International Classification:

C12Q 1/70
C12Q 1/68
A61K 39/21

US Classification:

435 5, 435 61, 4242081

Abstract:

The invention provides a method for determining whether a human immunodeficiency virus is likely to be have enhanced ability to enter a cell expressing CD4 and CXCR4 relative to a reference HIV. In certain aspects, the methods comprise detecting one or more amino acid in an envelope protein of the HIV associated with enhanced ability to enter CD4- and CXCR4-expressing cells and determining that the HIVs ability to enter such cells is enhanced relative to a reference HIV, e. g. , an HIV that does not comprise such amino acid(s).

US Patent:

20040063191, Apr 1, 2004

Filed:

Jul 1, 2003

Appl. No.:

10/612604

Inventors:

Wei Huang - Foster City CA, US
Mary Wrin - Fremont CA, US
Jeff Beauchaine - Daly City CA, US
Jeannette Whitcomb - San Mateo CA, US
Christos Petropoulos - Half Moon Bay CA, US
Neil Parkin - Belmont CA, US

International Classification:

C12N001/20

US Classification:

435/252300

Abstract:

This invention relates to compositions and methods for determining the replication capacity of a non-nucleoside reverse transcriptase inhibitor resistant virus. The compositions and methods are useful for identifying effective drug regimens for the treatment of viral infections, and identifying and determining the biological effectiveness of potential therapeutic compounds.

US Patent:

20040110125, Jun 10, 2004

Filed:

Jun 4, 2002

Appl. No.:

10/164290

Inventors:

Christos Petropoulos - Half Moon Bay CA, US
Neil Parkin - Belmont CA, US
Jeannette Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US

International Classification:

C12Q001/70
C12Q001/68

US Classification:

435/005000, 435/006000

Abstract:

The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

US Patent:

20080162592, Jul 3, 2008

Filed:

Dec 28, 2007

Appl. No.:

11/966078

Inventors:

Wei Huang - Fremont CA, US
Wenting Tang - Sunnyvale CA, US
Christian F. Beedgen - Cupertino CA, US

Assignee:

ARCSIGHT, INC. - Cupertino CA

International Classification:

G06F 17/30

US Classification:

707202, 707E17007

Abstract:

A logging system includes an event receiver and a storage manager. The receiver receives log data, processes it, and outputs a data “chunk.” The manager receives data chunks and stores them so that they can be queried. The receiver includes buffers that store events and a metadata structure that stores metadata about the contents of the buffers. The metadata includes a unique identifier associated with the receiver, the number of events in the buffers, and, for each “field of interest,” a minimum value and a maximum value that reflect the range of values of that field over all of the events in the buffers. A chunk includes the metadata structure and a compressed version of the contents of the buffers. The metadata structure acts as a search index when querying event data. The logging system can be used in conjunction with a security information/event management (SIEM) system.